Activity of 2 methoxyestradiol (Panzem NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial. (Q45939750)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Activity of 2 methoxyestradiol (Panzem NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19577796%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Activity of 2 methoxyestradiol (Panzem NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19577796%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

2-methoxyestradiol

1 reference

ChEBI release 2020-05-28

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

peritoneal carcinomatosis

1 reference

based on heuristic

inferred from title

Daniela E. Matei

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19577796%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Susan M. Perkins

4

object named as

Susan Perkins

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19577796%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Jeanne M. Schilder

2

object named as

Jeanne Schilder

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19577796%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

author name string

Gregory Sutton

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19577796%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Tim Breen

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19577796%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Check Quon

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19577796%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Carolyn Sidor

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19577796%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

language of work or name

0 references

publication date

4 July 2009

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19577796%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19577796%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

115

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19577796%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19577796%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

90-96

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19577796%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Cancer statistics, 2000.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.042

7 January 2021

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.042

7 January 2021

Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.042

7 January 2021

Role of angiogenesis in tumor growth and metastasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.042

7 January 2021

Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.042

7 January 2021

The biology of vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.042

7 January 2021

The influence of microvessel density on ovarian carcinogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.042

7 January 2021

Isolation and purification of vascular endothelial growth factor (VEGF) from ascitic fluid of ovarian cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.042

7 January 2021

Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with suspected ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.042

7 January 2021

VEGF and HIF-1alpha expression are increased in advanced stages of epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.042

7 January 2021

Expression of angiopoietin-1, angiopoietin-2, and Tie2 genes in normal ovary with corpus luteum and in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.042

7 January 2021

MT1-MMP and MMP-2 mRNA expression in human ovarian tumors: possible implications for the role of desmoplastic fibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.042

7 January 2021

2-Methoxyestradiol and analogs as novel antiproliferative agents: analysis of three-dimensional quantitative structure-activity relationships for DNA synthesis inhibition and estrogen receptor binding

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.042

7 January 2021

The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.042

7 January 2021

2-methoxyestradiol inhibits hypoxia-inducible factor-1{alpha} and suppresses growth of lesions in a mouse model of endometriosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.042

7 January 2021

2-methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.042

7 January 2021

Synthesis, antitubulin and antimitotic activity, and cytotoxicity of analogs of 2-methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymerization by binding to the colchicine binding site

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.042

7 January 2021

2-Methoxyestradiol suppresses microtubule dynamics and arrests mitosis without depolymerizing microtubules

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.042

7 January 2021

Roles of p38- and c-jun NH2-terminal kinase-mediated pathways in 2-methoxyestradiol-induced p53 induction and apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.042

7 January 2021

2-methoxyestradiol blocks cell-cycle progression at G(2)/M phase and inhibits growth of human prostate cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.042

7 January 2021

2-Methoxyestradiol and paclitaxel have similar effects on the cell cycle and induction of apoptosis in prostate cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.042

7 January 2021

A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.042

7 January 2021

Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.042

7 January 2021

Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.042

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.042

7 January 2021

Use of CA-125 to Assess Response to New Agents in Ovarian Cancer Trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.042

7 January 2021

Role of X-linked inhibitor of apoptosis protein in chemoresistance in ovarian cancer: possible involvement of the phosphoinositide-3 kinase/Akt pathway.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.042

7 January 2021

2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.042

7 January 2021

Effect of 2-methoxyestradiol on the growth of methyl-nitroso-urea (MNU)-induced rat mammary carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.042

7 January 2021

Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.042

7 January 2021

Class III beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.042

7 January 2021

Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.042

7 January 2021

Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.042

7 January 2021

Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.042

7 January 2021

beta-Tubulin mutations are associated with resistance to 2-methoxyestradiol in MDA-MB-435 cancer cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.042

7 January 2021

Class I beta-tubulin mutations in 2-methoxyestradiol-resistant acute lymphoblastic leukemia cells: implications for drug-target interactions

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.042

7 January 2021

ENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma(HCC) cells, and inhibits growth and vascularization in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.042

7 January 2021

On-chip, cell-based microarray immunofluorescence assay for high-throughput analysis of target proteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.042

7 January 2021

Significant antitumor activity in vivo following treatment with the microtubule agent ENMD-1198.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.042

7 January 2021

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45939750&oldid=1694442198"